227 Results

Serum IL-1β can be a biomarker in children with severe persistent allergic rhinitis.

Background: Allergic rhinitis (AR) is one of the most common diseases globally and usually persists throughout life. In the present study, we aimed to determine whether the expression of inflammatory biomarkers has a relationship...

Anti-IgE treatment in allergic rhinitis.

Objectives: To review the efficacy of anti-IgE therapy in allergic rhinitis (AR).

Methods: Literature search was performed using...

The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets.

Histamine and its receptors (H1R–H4R) play a crucial and significant role in the development of various allergic diseases. Mast cells are multifunctional bone marrow-derived tissue-dwelling cells that are the major producer of...

Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide.

Background: Atopic dermatitis (AD) is a heterogeneous disease with a multifactorial aetiology and complex pathophysiology. This heterogeneity translates into different trajectories of disease progression with respect to...

Efficacy of autologous whole blood or serum therapy for chronic spontaneous urticaria: A systematic review and meta-analysis.

Objective: We elucidated currently available evidence for the efficacy and safety of AWB therapy and AST for CSU.

Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.

Background: The real-life data on the effectiveness and safety of omalizumab in chronic spontaneous urticaria (CSU) with validated methods are scarce. There is also a lack of information on the use of combination treatments.

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.

Objective: To quantitatively synthesize what is known about the benefits and harms of omalizumab in the real-world clinical management of CIU regarding urticaria activity, treatment response, and adverse events.

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.

Objectives: To correlate baseline levels of two proposed biomarkers, total IgE (bIgE) and d‐dimer (bd‐dimer), and clinical parameters to omalizumab response and to relapses after drug withdrawal.

Relationship between vitamin D and chronic spontaneous urticaria: a systematic review.

Background: Vitamin D has been reported to be associated with many allergic diseases. There are a limited number of the studies of vitamin D supplementation in patients with chronic spontaneous urticaria (CSU).

Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.

Objective: To describe disease burden, quality of life (QoL), and treatment patterns of patients with H1‐antihistamine‐refractory CSU in Germany.

Load more